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Abstract
Prior to the identification of the various abnormal proteins deposited as fibrillar aggregates in the Alzheimer’s disease
(AD) brain, there was tremendous controversy over the importance of the various lesions with respect to primacy in the
pathology of AD. Nevertheless, based on analogy to systemic amyloidosis, many investigators believed that the amyloid
deposits in AD played a causal role and that characterization of these deposits would hold the key to understanding this
complex disease. Indeed, in retrospect, it was the initial biochemical purifications of the V4 kDa amyloid L-peptide (AL)
from amyloid deposits in the mid 1980s that launched a new era of AD research (Glenner and Wong, Biochem. Biophys. Res.
Commun. 122 (1984) 1121^1135; Wong et al., Proc. Natl. Acad Sci. USA 82 (1985) 8729^8732; and Masters et al., Proc.
Natl. Acad Sci. USA 82 (1985) 4245^4249). Subsequent studies of the biology of AL together with genetic studies of AD have
all supported the hypothesis that altered AL metabolism leading to aggregation plays a causal role in AD. Although there
remains controversy as to whether AL deposited as classic amyloid or a smaller, aggregated, form causes AD, the relevance of
studying the amyloid deposits has certainly been proven. Despite the significant advances in our understanding of the role of
AL in AD pathogenesis, many important aspects of AL biology remain a mystery. This review will highlight those aspects of
AL biology that have led to our increased understanding of the pathogenesis of AD as well as areas which warrant additional
study. ß 2000 Elsevier Science B.V. All rights reserved.
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1. AL isoforms in AD pathogenesis
1.1. AL plays a causal role in AD
A central question regarding the pathological
mechanisms underlying AD has been whether altered
amyloid L protein (AL) metabolism leading to AL
aggregation triggers the pathology observed in AD
or is an end stage product of that pathology. The
genetic forms of AD have been particularly helpful in
resolving this issue. If AL aggregation triggers the
development of AD pathology, then genetic altera-
tions that produce AD should be related to AL ag-
gregation. This relationship has proven to be the case
providing the strongest rationale for further studies
of factors that in£uence abnormal metabolism and
aggregation of AL in AD.
Although numerous proteins are associated with
the amyloid deposits in AD, the principal proteina-
ceous component of both plaque core and vascular
amyloid are aggregates of a V4 kDa polypeptide
referred to as AL. AL is a normally secreted, soluble,
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 0 ) 0 0 0 4 3 - 0
* Corresponding author. E-mail : tgolde@mayo.edu
BBADIS 61959 4-7-00
Biochimica et Biophysica Acta 1502 (2000) 172^187
www.elsevier.com/locate/bba
Fig. 1. (A) Processing pathways of APP. The APP is cleaved at the amino terminus of the AL sequence by an unknown protease re-
ferred to as L-secretase. This cleavage releases a large secreted derivative referred to as sAPPL. Subsequent cleavage of the APP CTF
(C99) by Q-secretase generates AL. In the K-secretory pathway, the APP is cleaved within the AL region to generate a large secreted
derivative referred to as sAPPK. Subsequent cleavage of the APP CTF (C83) by Q-secretase generates a truncated AL species referred
to as P3 beginning at the lysine at AL17. (B) AL and FAD-linked APP mutations. The AL region of APP is shown in detail. Muta-
tions in APP that are linked to FAD or HCHWA are indicated. The numbering of these mutations is based on the APP770 sequence.
A single asterisk at AL7 indicates the complement binding region of AL while the double asterisks indicate the residues involved in
microglial binding.
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proteolytic product of the 677^770 amino acid, type
1 integral membrane protein, referred to as the amy-
loid L protein precursor (APP), and is an internal
sequence within the APP beginning 99 amino acids
from the carboxyl terminus [4^10]. Generation of AL
from APP requires two proteolytic events, a proteo-
lytic cleavage at the amino terminus of the AL se-
quence referred to as L-secretase [11] and a cleavage
at the carboxyl terminus known as Q-secretase (Fig.
1A). To date, neither of the proteases responsible for
these activities has been de¢nitively identi¢ed. In
addition, a third proteolytic activity referred to as
K-secretase, cleaves within the AL sequence to release
a large secreted derivative thus precluding formation
of full-length AL. Recent data indicate that in mam-
malian cells at least two members of the ADAM
family of disintegrin metalloproteases can contribute
to the K-secretase activity [12,13]. While full-length
APP is not cleaved by Q-secretase, APP carboxyl ter-
minal fragments (CTF) generated through cleavage
of APP by either K- or L-secretase are both sub-
strates for Q-secretase with cleavage of the K-secretase
derived APP CTF releasing a peptide referred to as
P3 (AL17^40 or AL17^42) [5,8].
Comparison of the soluble AL secreted by cells,
soluble AL in CSF, and insoluble AL isolated from
the AD brain, has revealed that there are numerous
AL species with extensive amino and carboxyl termi-
nal heterogeneity (reviewed in [14]). The major
4-kDa species in both conditioned medium and hu-
man CSF is AL1^40 (s 60^70%), although some
AL1^42 (V15%) is also present along with minor
amounts of other peptides (e.g. AL1^28, AL1^33,
AL1^34, AL3^34, AL1^37, AL1^38, and AL1^39)
[15^17]. Although AL1^40 is the major species pro-
duced, the principal species deposited within the pa-
renchyma of the AD brain are species ending at
AL42 [18,19]. Thus, species ending at AL42, which
are a minor component of the AL that is normally
secreted by cells, in many cases constitute the bulk of
the AL that is deposited in the AD brain.
Compelling evidence that the AL is not a disease
marker, but plays a causal role in the development of
AD pathology, has come from studies showing that:
Table 1
E¡ect of APP and PS mutants on AL40 and AL42
Model Mutation Study Ref. Result
Transgenic mouse brain PS1 Borchelt et al. (1997) [31] Increase AL42/AL40 ratio by 50%
Citron et al. (1997) [24] Increase AL42/AL total ratio by 2 fold
Du¡ et al. (1996) [25] Increase AL42 by 31^34%
Qian et al. (1998) [101] Increase AL42
Nakano et al. (1999) [102] Increase AL42
PS2 Oyama et al. (1998) [103] Increase AL42
Transfected cells APPNL Citron et al. (1992); Cai et al. (1997) [21,104] Increase AL total 5^6-fold
APP717 Suzuki et al. (1994) [16] Increase AL42/AL40 ratio by 60%
APP716 Eckman et al. (1997) [95] Increase AL42
PS1 Borchelt et al. (1996) [23] Increase AL42/AL40 ratio 30^73%
Mehta et al. (1998) [26] Increase AL42
Citron et al. (1997) [24] Increase AL42/AL total ratio by 2-fold
Murayama et al. (1997) [105] Increase AL42/AL total ratio
PS2 Tomita et al. (1997) [27] Increase AL42
Plasma APPNL Scheuner et al. (1996) [22] Increase AL total 2^3-fold
APP717 Scheuner et al. (1996) [22] Increase AL42 2-fold
APP 716 Eckman et al. (1997) [95] Increase AL42
PS1 Scheuner et al. (1996) [22] Increase AL42 by 100%
PS2 Scheuner et al. (1996) [22] Increase A42 by 50%
Fibroblasts APPNL Citron et al. (1994; Johnston et al. (1994) [106,107] Increase AL total
PS1 Scheuner et al. (1996) [22] Increase AL42 by 350%
PS2 Scheuner et al. (1996) [22] Increase AL42 by 300%
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(1) mutations in the APP (see Fig. 1B), presenilin 1
(PS1) and presenilin 2 (PS2) genes that are linked to
the early onset forms of familial AD (FAD) increase
total AL [20,21] or speci¢cally increase the relative
amount of long AL peptides ending at AL42 [16,22^
27]; (2) APOE4, a major risk factor in typical late
onset Alzheimer’s disease, increases AL deposition
[28]; (3) long AL forms amyloid ¢brils more rapidly
than shorter species [29,30]; (4) over-expression of
familial AD-linked mutant APPs or co-expression
of mutant APP and familial AD-linked PSs in the
brains of transgenic mice leads to AL deposition
[31^36]; and (5) AL aggregates can directly and in-
directly mediate neurotoxic e¡ects, in£ammatory re-
sponses and abnormal tau phosphorylation (re-
viewed in [37]). Table 1 lists the various alterations
in AL induced by mutations that have been reported
by our groups and others. As demonstrated by these
studies, all APP and PS mutations consistently alter
AL metabolism in a manner likely to enhance AL
aggregation and ultimately lead to amyloid deposi-
tion.
1.2. AL40 in AD pathogenesis
Although genetic evidence supports a causal role
for AL42 in AD pathogenesis, genetic studies have
not provided as much evidence to de¢nitively sup-
port a pathogenic role for AL1^40. However, signi¢-
cant amounts of AL1^40 and amino terminally trun-
cated forms ending at AL40 (ALX-40) are deposited
as amyloid in the typical late onset AD brain, and in
most studies AL1^40 appears to be the most abun-
dant peptide in cerebrovascular amyloid deposits ^
indicating that AL40 may also play a role in AD
pathogenesis. Interestingly, several studies examining
the role of APOE on amyloid deposition ¢nd that
APOE4 in£uences AL40 deposition rather than AL42
suggesting that APOE4 may lower the threshold for
¢brillization of AL40, thereby promoting its subse-
quent deposition [38,39]. Thus, although the total
amount of AL initially deposited in the brain as
AL42 is not a¡ected by the binding to a particular
APOE isoform, the presence of APOE4 in£uences
the subsequent maturation of plaques with a greater
proportion transforming into AL40 containing cored
plaques when the E4 isoform is present. Given that
the major di¡erence in AL40 and AL42 species is
their di¡erent rates of ¢bril formation, it is likely
that both AL40 and 42 contribute to AD pathogen-
esis, but that AL40 deposition requires additional
factors, such as the presence of APOE4 or prior
seeding by AL1^42 to foster its deposition.
One of the intriguing aspects of AL40 is its pref-
erential deposition in the cerebrovasculature. While
some AL42 is deposited in cerebral vessels [40], in
brains where parenchymal amyloid deposits are pri-
marily composed of ALX-42 species, the cerebral ves-
sels typically contain predominantly ALX-40 [18,19].
Signi¢cantly, the APPE693Q mutation associated with
hereditary cerebral hemorrhage with amyloidosis of
Dutch Origin (HCHWA-D) [41] does not signi¢-
cantly alter AL production [42], but results in accel-
erated deposition of the mutant AL1^40 in the cere-
brovasculature. Rather than altered production, in
HCHWDA a mutant AL peptide seems responsible
for induction of pathology, a notion which is sup-
ported by studies demonstrating that these mutant
peptides aggregate more readily than non-mutant
AL [43]. But why does the mutant HCWDA-D
AL1^40 deposit more readily in cerebral vessels
than in the brain parenchyma? To complicate mat-
ters even more, another mutant associated initially
with HCHWA (A692G) actually results in a some-
what mixed phenotype, exhibiting extensive vascular
amyloid deposition along with parenchymal amyloid
deposition [44]. This mutant appears to alter AL pro-
duction by partially inhibiting K-secretase cleavage
resulting in increased AL and decreased P3 [42,45].
Several amino terminally truncated species were also
increased by this mutant. Again, however, the ques-
tion remains as to why this mutation results in pref-
erential deposition in the cerebrovasculature. At the
present time there is no de¢nitive answer.
1.3. Pathogenicity of AL isoforms and modi¢ed AL
peptides in the AD brain: beyond AL40 and AL42
Study of familial forms of AD have borne out the
importance of the ability to accurately distinguish
between AL species of various lengths, ¢rmly estab-
lishing a pathogenic role for ‘long’ AL species ending
at AL42 (reviewed in [46]). Yet, multiple AL peptides
with varying carboxyl and amino termini are pro-
duced and deposited in the AD brain, and deposited
AL peptides can undergo several modi¢cations in-
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cluding pyrolization [47^50], oxidation, isomerization
[51], and partial proteolytic degradation. Unfortu-
nately, little is known about the potential role that
various truncated AL species and modi¢ed AL pep-
tides play in the development of AD. For example, a
modi¢ed amino terminally truncated AL peptide be-
ginning with a pyroglutamate at position Glu-3
(ALpE3^42) appears to be the principal species
present in the amyloid deposits in typical late onset
AD [48], but the signi¢cance of this modi¢ed form
has not been established. Are truncation or pyroliza-
tion important factors determining whether AL is
deposited? Are these forms more toxic? More stable?
Or are these modi¢cations neutral events playing no
real role in pathogenesis, just the inevitable result of
aggregated AL sitting in the brain for long periods of
time [52]? Similar questions can be asked for other
AL species deposited in the brain and it is likely that
many additional studies will be needed to determine
the pathogenic role of each. Unlike the role of AL42,
which was ¢rmly established by study of genetic
forms of AD, determining the pathogenicity of trun-
cated and modi¢ed AL is likely to be a di⁄cult en-
deavor requiring integration of pathological studies
with in vitro and in vivo modeling studies.
At the present time, some insight into the role (or
lack thereof) of a few of the various AL peptides
deposited in the AD brain can be inferred from
pathological studies of amyloid deposits in human
brains and transgenic mouse models. An illuminating
example is the case of AL peptides found in di¡use
plaques. In both AD and control patients di¡use AL
deposits exist. These di¡use deposits contain immu-
noreactive AL peptides that are not stained by Con-
go-red. At the EM level, both ¢brillar and non-¢bril-
lar morphologies have been reported [53,54]. In the
past, it had been hypothesized that these di¡use de-
posits might be precursors of more compact amyloid
in classic senile plaques; however, studies in trans-
genic mice suggest the two deposits are distinct.
Although the two may eventually be superimposed
as each deposit becomes more abundant in the brain,
compact plaques appear to begin as compact depos-
its and di¡use deposits remain di¡use [32,55,56]. Fur-
thermore, in human brain, the principal species de-
posited in the di¡use plaques appears to be AL17^42,
a species not commonly found in compact amyloid
within neuritic plaques [57]. Finally, because di¡use
plaques are not associated with extensive neuritic
dystrophy and are present in the brains of non-de-
mented individuals, it might be inferred that deposi-
tion of AL17^42 is not pathogenic or at least not as
pathogenic as longer forms of AL.
In contrast to these studies on di¡use amyloid,
which suggest a non-pathogenic role for P3-like de-
rivatives, is a very recent report characterizing the
e¡ects on AL production of the newly discovered
FAD-linked APPV715M mutation [58]. This mutation
appears to increase AL species X-42 and not full-
length AL. While the exact amino terminus of these
X-42 species was not determined, based on migration
on a polyacrylamide gel, their size was consistent
with the P3-like peptides. These data indicate that
increased production of amino terminally truncated
AL species may also cause AD. However, this con-
clusion may be premature as no analysis of the AL
deposited in the brains of an a¡ected carrier of the
APPV715M had been performed. Only upon de¢nitive
characterization of the amino terminus of the trun-
cated AL species in model systems and analysis of the
AL peptides deposited in brain tissue of an a¡ected
carrier will such conclusions be possible.
Except for these later studies on the APPV715M
mutations, most studies of AL are consistent with
the hypothesis that the amino terminus of AL may
mediate many of the pathogenic responses to amy-
loid deposits, such as microglial activation and in-
£ammation [59]. In support of this idea the aspartate
at position 7 appears to be necessary for C1q binding
and activation by ¢brillar AL [60^62] and AL resi-
dues 13^16 (HHQK) appear necessary for activation
and binding by microglial cells [63] (Fig. 1B). Thus,
while carboxyl terminal variation may critically in£u-
ence AL deposition, the amino terminus may in£u-
ence the biological response to deposited amyloid. In
this regard, the newly described APPV715M mutant
may well ¢t into this paradigm if the P3-like deriva-
tives overproduced by this mutant aggregate and
then seed deposition of the full-length AL peptides.
1.4. Intracellular AL in AD pathogenesis
Studies demonstrating that AL42 is made selec-
tively in the ER, that AL42 is the principle species
present intracellularly, and that neuronal cells have
the highest amounts of intracellular AL, prompted
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speculation that intracellular AL may play a patho-
genic role in AD [64^67]. Unfortunately, studies that
would de¢nitively support this notion have not been
forthcoming. Indeed, for several reasons this is a very
di⁄cult issue. First, as discussed in detail later, de-
tection and quantitation of intracellular AL remains
problematic. Second, it is hard to design a truly com-
pelling study that could demonstrate that it is intra-
cellular AL and not extracellular AL doing the dam-
age. For example, how does one distinguish cell-
associated AL from intracellular AL, or re-internal-
ized AL from AL produced and stored in an intra-
cellular pool? Finally, it is hard to envision how
APOE, a secreted lipoprotein, would interact with
intracellularly derived AL and in£uence amyloid dep-
osition. Although APOE could interact with AL in
the endosomal pathway, it is likely that this pathway
would not result in selective interaction with true
intracellular AL (i.e. AL that has not been secreted
and re-internalized).
More recently, intracellular AL has also been de-
tected in detergent insoluble glycosphingolipid mem-
branes (DIGS) and caveolar-like membranes [68^70],
and in the Alzheimer’s brain AL has been found to
be complexed with GM-1 ganglioside, a major con-
stituent of DIGs and caveolar-like membranes [71^
73]. These studies are intriguing in that the conver-
sion of PrPc to PrPsc has been postulated to occur in
such membranes [74] and ganglioside enriched mem-
branes have been shown to accelerate AL formation
[75,76]. Thus, it has been postulated that DIGs may
serve as sca¡olds for AL ¢bril formation. Again fur-
ther studies will be needed to determine the exact
role of DIGs in AL formation and deposition.
Analyses of the pathogenic e¡ects of PS1 mutants
in human and mice highlight the importance of rig-
orous studies of intracellular AL. In most cases,
FAD-linked PS mutants increase classical forms of
AL deposition in the brain, but in some families with
a PS1v exon 9 mutation non-classical ‘cotton wool’
AL containing plaques that do not have a congophil-
lic dense core or marked plaque-related neuritic
pathology are predominant [77]. This study raises
the possibility that AL deposited as classic amyloid
may not be the culprit in AD, but rather some other
form such as membrane bound AL, soluble AL olig-
omers, or even intracellular AL. Furthermore, a very
recent report characterizing PS1L286V mutant mice
also demonstrates that overexpression of this PS1
mutation in transgenic mouse brains increases neuro-
degeneration in the absence of overt classical amy-
loid deposition as assessed by anti-AL immunohisto-
chemistry. However, intracellular AL, detected
immunohistochemically by a polyclonal antibody
that recognizes AL42, was shown to be increased in
some neurons in these mice. Unfortunately, no bio-
chemical analyses of the AL was performed in either
of these studies. In the PS transgenic mice, this raises
questions as to whether the accumulating, immuno-
reactive, species was truly AL42 or some other APP
derivative, for example an AL-like peptide produced
by cleavage of APP CTF by caspases [78,79]. Clearly,
this distinction is important. Is intracellular AL the
culprit in AD cases linked to PS? Can PS cause
neuronal death independent of AL, and if mutant
PS do cause neuronal death independent of AL in
model systems, is such an e¡ect apparent in the
AD brain? Currently, such questions have no de¢n-
itive answers. However, more extensive analyses of
brains with non-classic AL deposits and animal mod-
els such as the PS mice described above should help
to determine the true pathogenic form of AL.
1.5. Re¢ning the amyloid hypothesis
A growing body of evidence highlighted by the
analysis of brain tissue from individuals a¡ected by
the PS1v exon 9 deletion mutation suggests that AL
deposition in classical congophillic amyloid deposits
may not be not necessary for neurodegeneration [77].
This evidence has resulted in some reworking of the
original amyloid cascade hypothesis. Rather than AL
deposition as amyloid leading to AD pathology, it is
now more parsimonious to say that AL aggregates
lead to AD pathology. However, the truth, at this
time, is that we do not really know what form of AL
mediates the pathological cascade. In these rare ge-
netic cases, it certainly appears that classical amyloid
deposits do not mediate the pathology, but this does
not necessarily mean that congophillic deposits may
not play a pathological role in the typical late onset
AD patient. Much of the di⁄culty with respect to
such distinctions can be attributed to the discrepancy
observed between in vitro studies demonstrating
toxic e¡ects of AL aggregates and the lack of overt
toxicity observed in animal models of AL deposition
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and studies that have demonstrated a poor correla-
tion between plaque load and clinical signs of demen-
tia. While it is generally acknowledged that animal
models may never fully recapitulate all aspects of AD
pathology, further study and development of such
models is clearly needed in order to understand
what factors account for the di¡erential e¡ects of
AL applied to cells in vitro versus AL aggregate for-
mation in vivo. In this respect, a recent study show-
ing that primate neurons are more sensitive to AL
toxicity than rodent neurons and that aged neurons
in general are more sensitive to AL toxicity is partic-
ularly intriguing as it suggests that there are both
primate-speci¢c and age-speci¢c factors that modu-
late the response to AL [80]. In addition, it is likely
that rigorous analysis of AL species and types of
aggregates deposited in brains of individuals without
evidence of neuronal loss or clinical signs of demen-
tia will enhance our understanding of what forms of
AL contribute to pathology and what forms do not.
2. Biochemical detection of AL
2.1. Introduction
Because genetic forms of AD can be caused by
small changes in production of a minor AL species,
the ability to accurately detect and quantitate various
AL peptides is of paramount importance. Over the
years, multiple biochemical techniques been devel-
oped for detection of various AL peptides (see Tables
2 and 3), and with the advent and wide availability of
many highly speci¢c and sensitive antisera to various
epitopes of AL, the detection and discrimination of
AL species has certainly become more routine ^ es-
pecially when AL levels are high (s 100 pM). How-
ever, each of the techniques described below has lim-
itations and drawbacks, especially with respect to the
detection of endogenous AL peptides in biological
£uids such as plasma.
2.2. Detection of AL peptides after PAGE
AL peptides can be readily detected by Western
blotting or immunoprecipitation of metabolically la-
beled AL after separation on gel systems such as
Tris-Tricine [81] that facilitate the separation of small
peptides [5,8]. While the sensitivity of metabolic la-
beling/IP detection of AL is high, the utility of West-
ern blotting is somewhat limited by sensitivity issues
as the limit of detection is V100 fmol of AL. Also,
metabolic labeling/IP of AL is largely limited to in
vitro systems where cells can be readily metabolically
labeled. On the other hand, the ability to size AL
peptides and separate them from other AL deriva-
Table 2
Utility of various techniques in measuring AL from various sources
Source of AL Western blotting Metabolic labeling/IP ELISA IP/mass spectrometry
AD brain (100^10 000 pM/g AL) +++ NA +++ +++
Control brain (6 10 pM/g AL) +/3 NA +++ +/3
Media of transfected cells (s 100 pM AL40,
s 25 pM AL 42
++ (requires IP) +++ +++ +++
Media of non-transfected cells 3 +/3 ++ +/3
(6 100 pM AL, 6 25 pM AL42) ++ (requires IP) NA +++ +++
Urine [108] 3 3 + ?
Non-transgenic mice 3 3 +b
Transgenic APP mice 3 +a +++ ++
Human plasma 3 NA +++ 3
Intracellular AL 3 +/3 + 3
The utility of these techniques for the detection of AL is indicated by the following symbols: 3 indicates the technique is not useful;
+/3 indicates the technique has been used with very limited success; + indicates the technique is applicable but is subject to experi-
mental constraints; ++ indicates the technique will work in most, but not all, instances; +++ indicates that this is a preferred tech-
nique for AL detection. NA indicates not applicable.
aAlthough such in vivo labeling experiments are feasible, they are not routinely performed.
bNot all ELISA systems are su⁄ciently sensitive to measure endogenous AL which is typically present in mouse brain at concentra-
tions 6 2 pmol/g.
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tives is particularly useful in the detection of amino-
terminally truncated AL peptides (such as P3) whose
speci¢c detection by ELISA remains problematic.
Signi¢cantly, some gel systems have been developed
that enable separation of AL1^40 and AL1^42 [82];
however, caution must be used when employing these
systems as the migration of AL species other than
AL1^40 and AL1^42 on these gels has not been es-
tablished.
Detection of AL after PAGE continues to hold
some promise for detecting both large aggregates
and small oligomeric forms of AL [83,84]. Although
chromatographic techniques based on size exclusion
may be more appropriate for separation of large ag-
gregates, PAGE remains highly useful for detection
of the smaller multimers of AL that can be isolated
from brain and conditioned media in CHO cells
transfected with APP [83,84]. Given the interest in
small oligomeric species as well as larger proto¢bril-
lar forms of AL as potential mediators of AL toxicity
[37,85], PAGE separation and other chromato-
graphic techniques will continue to be used to study
these less well characterized forms of AL unless addi-
tional techniques are developed.
2.3. AL detection by sandwich ELISA
Perhaps the most widely applicable of the tech-
niques for the detection of AL are the sensitive sand-
wich ELISAs that have been developed. Especially
useful have been those systems which enable speci¢c
detection of AL40 and AL42 through the develop-
ment of end-speci¢c antibodies [16,35,86,87]. These
ELISAs marked a pivotal technical development
that enabled dissection of the e¡ects of the various
FAD-linked APP and PS mutants on AL processing.
Fig. 2 illustrates the sandwich ELISA technique. The
sensitivity, speci¢city, accuracy and throughput of
these systems, make them the system of choice for
measurements of AL from most biological samples;
some systems are capable of detecting 1 pM or less
of a given AL peptide. However, these ELISA sys-
tems can be problematic when attempting to detect
low concentrations of AL in the presence of other
APP derivatives that may compete for binding with
the capture antibody or be recognized by the detec-
tion antibodies. Furthermore, because no e¡orts to
standardize the various systems have been made,
cross comparison of results obtained with one system
(or even with the same system used in di¡erent labo-
ratories) remains problematic. Thus, while consensus
may be reached on the relative levels of AL as deter-
mined by an AL42/AL40 ratio, the absolute level of
AL detected may vary considerably from one labo-
ratory to another. Given the variability of synthetic
AL, it is likely that much of the variance in ELISA
quantitation are in fact due to the di¡erent AL syn-
thetic standards employed in individual laboratories.
Because many of the capture antibodies used in
these systems will bind to other APP derivatives
Table 3
Detection of AL isoforms by various techniques
AL Species Western blotting Metabolic labeling/IP ELISA IP/mass spectrometry
Total AL ++ ++++ ++++ ++++
P3 (17^40 or 17^42) ++ ++++ ++ +/3
AL1^40 ++a +++a ++++ ++++
AL1^42 +a ++a +++ +/3
Interference by other APP derivatives
(e.g. sAPP)
Not likely Not likely Possible Not likely
Other AL peptides 3 +/3 ++b ++++
Intracellular AL 3 + +/3 +/3
Aggregated ALc ++ + ++d ??
aRequires end-speci¢c antibodies or use of specialized gel electrophoresis conditions.
bCan be inferred by comparing amount of total AL to other species detected with end speci¢c antibodies.
cOther techniques, such as size exclusion chromatography or £uorescence correlation spectroscopy, may be more useful for detection
of large aggregates (see text).
dAlthough direct detection of aggregated AL has not yet been reported by ELISA, AL aggregates can be solubilized in 70% formic
acid or 2% SDS and then measured in some ELISA systems.
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such as sAPPK and APP holoprotein, when using
any AL ELISA it is important to consider whether
AL is being speci¢cally detected and whether the
presence of other APP derivatives will alter quanti-
tative analyses. For this reason, it is important to
initially validate results obtained by ELISA with ad-
ditional techniques. In the past, our groups have va-
lidated AL ELISAs by showing that 4-kDa AL pep-
tides are being detected in the sample [16,18]. This
validation involved the physical separation of AL
peptides using RPLC to purify the AL peptides prior
to ELISA analysis. By calibrating the RPLC separa-
tion with synthetic AL standards, we were able to
show that the ELISAs (e.g. Ban-50 capture and
BA-27 or BC-05 detection) were only reacting with
material that eluted o¡ the RPLC column under the
same conditions as the synthetic AL standards. Cau-
tion is especially warranted when using many of the
newer ELISA systems either available commercially
or reported more recently in the literature since these
have not been as extensively validated. Such valida-
tion is important, for example, in the detection of
intracellular AL where controversy still exists as to
what is being measured by ELISA. Immunoprecipi-
tation of metabolically labeled cellular lysates with
anti-AL antisera used as capture antibodies reveals
that the 4-kDa AL bands is only a minor immuno-
precipitated band co-precipitated with numerous oth-
er higher molecular weight proteins ^ indicating that
other APP derivatives or cross reactive proteins can
bind to the capture antibody (Golde and Eckman,
unpublished data). This competition for binding to
the capture antibody could either falsely elevate or
depress the AL signal generated from the ELISA. If
non-speci¢c proteins are binding to the capture anti-
body, then the signal will likely be falsely depressed.
However, if APP derivatives are binding to the cap-
ture antibody, the AL signal may be either falsely
elevated or depressed depending on whether the
APP derivatives being captured are recognized by
the detection antibody.
2.4. AL analysis by IP/mass spectrometry
IP/mass spectrometry (MS) has proven to be quite
useful for the de¢nitive identi¢cation of AL peptides,
but requires access to specialized instrumentation
[15]. Typically, AL is immunoprecipitated using a
monoclonal anti-AL antibody coupled to a Sephar-
ose bead, released from the bead in an organic sol-
vent, and then analyzed by MS. With the appropri-
ate use of internal standards, de¢nitive identi¢cation
of most AL peptides is possible as the technique is
accurate to within a single Dalton. Although quanti-
tative analyses are possible with MS, the sensitivity
of detection for each AL species varies, requiring ex-
tensive and often impractical development of syn-
thetic standards for each AL peptide. Where MS is
Fig. 2. AL sandwich ELISA. (A). A capture antibody is bound
to a 96-well plate. After blocking, the plate is then incubated
with media containing AL. (B) After incubation, AL species
containing epitopes recognized by the capture antibody are
bound to the antibody, while unbound proteins are removed by
washing. (C) Bound AL is subsequently detected using a detec-
tion antibody that recognizes an epitope that does not overlap
with the capture antibody. For detection of AL40 and AL42,
antibodies that speci¢cally recognize these species can be used
as detection antibodies (e.g. BA-27 for AL40 and BC-05 for
AL42). For detection of total AL an antibody that shares a
common epitope is typically used (e.g. 4G8 which recognizes an
AL17^24). These detection antibodies are typically directly
coupled to an enzymatic reporter, such as HRP. However, al-
ternative methods can be used to quantitate the amount of de-
tection antibody bound. Values obtained from these sandwich
ELISA assays are converted to AL concentrations by employing
appropriate AL synthetic standards.
BBADIS 61959 4-7-00
T.E. Golde et al. / Biochimica et Biophysica Acta 1502 (2000) 172^187180
especially useful is in examining the relative peak
heights of various peptides between two samples, en-
abling accurate pro¢ling of what is happening to
each individual species relative to another (Fig. 3
and [88]).
2.5. Analysis of AL aggregates
AL aggregation into amyloid appears to be a nu-
cleation-dependent polymerization which may pre-
cede through a proto¢brillar intermediate
[29,89,90]. In addition, recent reports indicate that
small AL aggregates may mediate AL induced neuro-
toxicity [91]. These studies have raised many ques-
tions regarding what form of amyloid is really caus-
ing AD. Is it the classic amyloid deposits? Is it a
smaller soluble or cell-associated aggregate that is
the o¡ending agent? If it is a smaller aggregated
form, what is its structure? Is it an oligomer or
more akin to a proto¢bril? Alternatively, do various
Fig. 3. Mass spectral detection of AL peptides: utility in detecting changes in the pro¢le of AL peptides. IP/MS spectra of AL peptides
secreted by 293T cells expressing APP695NL (A,B) and an APP mutant I637P (C,D) are shown. The I637P mutant is made in the
background of APP695NL, but contains mutation of isoleucine to proline at AL41. Spectra are shown for cells treated with DMSO
(vehicle) (A,C) or pepstatin (an inhibitor of Q-secretase activity) (B,D). For each pair of spectra, DMSO vs. pepstatin, the peak heights
of AL peptides are ¢rst normalized to the internal standard, AL(12^28) (labeled as 12^28 (Std)). The spectra are then plotted using
the relative peak intensities ; e.g. the highest peak within the pair of spectra is plotted as 100%. In this way, the relative intensity of
peaks between the two spectra can be compared. Peaks in the spectra are labeled with AL peptide sequence numbers based on the
wild-type AL sequence. Background peaks labeled with asterisk (*). These spectra illustrate the utility of IP/MS techniques to pro¢le
AL peptides and determine the e¡ects of various treatment on a given AL peptide species. In this particular experiment, pepstatin
treatment reduces total AL production from cells transfected with APP695NL by V80% (as measured by ELISA). The spectra shown
above indicate that pepstatin treatment reduces the amounts of each AL peptide produced by APP695NL to nearly equivalent levels.
In cells transfected with the APP mutant I637P, Q-secretase cleavage is shifted and the major AL species produced are AL1^37 and
AL1^43. In contrast to the e¡ect of pepstatin on Q-secretase cleavage of APP695NL, pepstatin treatment does not alter the amount of
total AL (measured by ELISA) produced by the I637P mutant. However, IP/MS analysis indicates that pepstatin treatment does alter
the pro¢le of AL peptides produced, increasing the relative amount of AL1^43 and decreasing the amount of AL1^37. (These data are
adapted from [85].)
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forms of aggregated AL contribute to AD pathol-
ogy? Given the potential importance of distinguish-
ing between various AL aggregates (e.g. proto¢brils
vs. amyloid ¢brils vs. small AL oligomers) additional
biochemical techniques will need to be developed
that will enable rapid distinction and sensitive detec-
tion of these forms. While small oligomers can be
distinguished from larger aggregates by PAGE, and
proto¢brils from larger aggregates by size-exclusion
chromatography, precise quantitation of these vari-
ous forms remains problematic. Although one might
envision development of ¢bril-speci¢c antibodies or
perhaps even antibodies capable of distinguishing be-
tween oligomers, proto¢brils, and ¢brillar AL, suc-
cessful attempts to raise such ¢bril speci¢c antisera
have, so far, not been reported. One promising tech-
nique with respect to detection and quantitation of
AL aggregates is £uorescence correlation spectrosco-
py, which was recently used to demonstrate the pres-
ence of aggregated AL species in AD CSF [92].
3. AL: a biomarker for AD?
One of the signi¢cant questions that remains in the
AD ¢eld is whether AL is an ideal biomarker for
AD. In the recent Consensus Report of the Working
Group on ‘Molecular and Biochemical Markers of
Alzheimer’s Disease’, it was recognized that although
many molecular and biochemical markers for AD
have been proposed, none has achieved universal ac-
ceptance or, for that matter, met the proposed crite-
ria for an ideal biomarker [93]. Of all the markers
discussed, plasma AL measurements continues to
hold the most promise, meeting most of the stated
criteria. In fact, previous studies by members of this
group and others have established that plasma AL
measurements are an ideal biomarker for individuals
within chromosome 1 and chromosome 14 FAD-
linked kindreds and individuals carrying the
APPK670N;M671L APP716, or APP717 mutations
[22,27,94,95]. While both AL40 and AL42 are in-
creased in plasma of carriers of the APPK670N;M671L
mutation, plasma AL42 levels are selectively in-
creased in individuals within chromosome 1 and
chromosome 14 kindreds and in those individuals
with APP716 and APP717 mutations. Signi¢cantly,
the initial studies on the chromosome 1 and 14 kin-
dreds preceded the identi¢cation of the mutant pre-
senilin (PS) genes in those kindreds, resulting in the
prediction that FAD-linked mutations in the a¡ected
genes would increase AL42 production [22]. This pre-
diction has subsequently been borne out in numerous
studies of PS mutations in cell culture systems and
transgenic animal models. In addition, plasma AL is
elevated in individuals with DS (trisomy 21) who
invariably develop AD pathology.
These studies on plasma AL in genetically driven
forms of AD suggest that plasma AL levels might be
as useful a biomarker for AD as serum cholesterol
levels are for atherosclerotic disease. Indeed, if plas-
ma AL can be shown to re£ect changes present in
CNS AL, then it potentially ful¢lls all of the criteria
for an ideal AD biomarker. Given the correlation
between cholesterol levels and risk for atherosclerotic
disease, we might predict that premorbid plasma AL
levels may correlate with risk of developing AD. Just
as HDL:LDL ratios predict risk for atherosclerotic
disease, we might also expect that AL40:42 ratios
might predict the risk for AD. Finally, to extend
this analogy to its fullest extent, one might also pre-
dict that in most cases where high plasma AL levels
or large selective increases in AL42 are seen, a genetic
abnormality in the metabolism of AL will be the
underlying cause ^ just as a cholesterol level of
s 400^500 mg/dl indicates an underlying genetic al-
teration.
In contrast to the studies on familial forms of AD,
initial studies on typical, late onset AD failed to ¢nd
a signi¢cant increase in mean AL levels in plasma or
CSF. Indeed, studies of CSF in AD have typically
reported declines in total AL, AL 42 or both. Given
these ¢ndings, serious questions regarding the utility
of plasma and CSF AL as a biomarker have been
raised. If increased AL levels are a risk factor for
AD, then why are AL levels not elevated in AD?
Our group and others have recently begun studies
to determine exactly why this is so. The initial results
of these studies are certainly encouraging, indicating
that AL levels may be elevated in patients prior to
and during the development of AD and that plasma
AL levels may ultimately predict risk for AD.
The reason that initial studies failed to detect sig-
ni¢cant increases in plasma and CSF AL is that lev-
els of AL in both appear to fall with progression of
disease. There is an emerging picture that CSF and
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plasma AL can be elevated in a signi¢cant percentage
of AD patients with early AD and that levels decline
with either increasing degree of cognitive impairment
or increasing disease duration. The initial report that
this might be the case came from studies of CSF in
patients with the APPK670N;M671L mutation. In these
patients, CSF AL was elevated, but the levels de-
clined with disease duration. More recent studies
now ¢nd that in sporadic AD, CSF AL42 levels are
elevated in many patients with mild AD or mild cog-
nitive impairment and decline in moderate to severe
AD [96^98]. No change or slight decreases in AL40
were seen in CSF from AD patients. In our analysis
of plasma AL a similar but distinct picture emerges:
a subset of patients with AD of short duration have
elevated plasma AL, but patients with disease of long
duration do not. Furthermore, in the Tg2576 trans-
genic mouse model of AL deposition in which the
APPK670N;M671L is expressed under control of CNS
speci¢c promoters, human AL is readily detected in
the plasma, and as these mice age and begin to de-
posit both AL40 and AL42 in the brain, plasma AL40
and AL42 decline [99].
The ¢nding that plasma AL and CSF levels are
high in some AD patients with short duration of
disease, but not in patients with long duration dis-
ease may explain why it is di⁄cult to ¢nd an associ-
ation between patients with AD and high AL levels.
Some patients with AD may have had high plasma
and CSF AL presymptomatically or in early stage
AD, but as the disease progressed, AL levels fell
into the control range. Biologically this could be ex-
plained by several phenomena occurring in the AD
brain: AL may be sequestered in the amyloid depos-
its (resulting in a decrease in the levels of soluble AL)
or may form small aggregates which are not detected
by the ELISA systems currently used. Depositing AL
may also be removed by microglia resulting in in-
creased CNS clearance, or net AL production may
be decreased as APP expressing neurons dysfunction
and die.
Another confounding factor in these analysis is the
¢nding by our group that plasma AL levels change
with aging in control patients. Thus, aged controls
exhibit both greater variance and higher mean levels
of plasma AL. This increased variance raises the pos-
sibility that AD patients who may have had elevated
AL levels presymptomatically when compared to
young controls are even more likely to have plasma
AL levels that have fallen into the age-matched con-
trol range. If this was the case prior to the onset of
symptoms then individuals at risk for developing AD
may have high plasma AL. Since family history is a
major risk factor for the subsequent development of
AD, it may be that genetic factors would determine,
at least partially, AL levels. We have therefore begun
to measure plasma AL in ¢rst-degree relatives of AD
patients and their families. These data show that
plasma AL40 and AL42 levels are signi¢cantly ele-
vated in ¢rst-degree relatives, and that some families
with AD probands have high plasma AL levels that
appear to be transmitted in a complex genetic fash-
ion through multiple generations [100]. These studies
suggest that high plasma AL may place individuals at
greater risk for the development of AD and that
inheritable genetic factors control AL levels.
Despite these ongoing studies the potential prom-
ise of plasma AL as a potent biomarker of AD re-
mains unful¢lled. The major question ‘Does plasma
AL predict risk for or aid in the diagnosis of AD?’
remains unanswered. Our recent studies and those of
others point to complex changes in AL levels that are
in£uenced by genetic factors, the AD disease process
itself, and aging. Because of this complex regulation
of AL levels, the answer to this important question
will likely only arise from long-term prospective
studies of plasma AL in relationship to the develop-
ment of AD. Given the data that are now emerging,
it would seem that such studies are warranted.
4. Measurement of AL in treatment of disease
Rational therapeutic approaches to treating AD
are currently being developed that target AL produc-
tion. Such approaches will certainly rely on measure-
ment of AL, either in plasma or CSF to document
e⁄cacy. However, one of the dilemmas currently fac-
ing the pharmaceutical industry is who to treat with
such drugs. If one treats patients with early AD,
might such anti-AL therapy be too little too late?
Clearly if the process is reversible, then such treat-
ment may be successful. However, anti-AL therapy
may require identi¢cation of individuals at risk prior
to the development of disease. Again, the analogy to
atherosclerotic disease is quite relevant. By the time a
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patient is symptomatic with angina, the coronary
artery is already at least 95% occluded and a bypass
or other physical intervention is needed ^ not a cho-
lesterol lowering agent. If this is the case with AD,
then a major investment needs to be made in devel-
oping predictive tests for who will get the disease so
that early pharmacological intervention can be initi-
ated. Clearly plasma AL holds potential in this re-
gard, but just as in atherosclerotic disease, it is likely
that AL levels, if proven to be useful, will not be used
in isolation, but rather in conjunction with a battery
of predictive tests (such as APOE genotyping).
5. Summary
The accurate detection and quantitation of various
AL isoforms has proven critical to our understanding
of the role AL plays in AD, and enabled rationale
therapeutic strategies to be developed based on
agents designed to lower AL production or disrupt
the aggregation of AL into ¢brils. It is clear that
techniques developed to detect AL to understand its
biological role will now ¢nd a signi¢cant role in de-
termining the e⁄cacy of therapeutic agents designed
to lower AL levels and possibly in predicting risk for
AD based on plasma AL levels. However, continued
technological improvements in our methods to detect
AL and AL aggregates are still needed as many ques-
tions remain regarding how various forms of AL may
contribute to AD pathology.
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